Anticancer research
-
Anticancer research · Feb 2010
Multicenter StudyPhase II study of erlotinib in Japanese patients with advanced non-small cell lung cancer.
The aim of this study was to evaluate the efficacy and safety of erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor, in Japanese patients with relapsed or recurrent advanced non-small cell lung cancer (NSCLC). ⋯ Erlotinib has promising antitumour activity and is generally well tolerated in Japanese patients with previously treated NSCLC.